Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adju🍬sted profits beating expect💃ations while the company's sales projections for the coming fiscal year fell short.

The drug and medical device maker reported $22.52 billion in revenue, in line 澳洲幸运5官方开奖结果体彩网:with analyst estimates compiled by Visible Alpha. The company's profits fell short, however, at $3.43 billion, or $1.41 per share, while analysts had expected $4.41 billion and $1.79 per share.

After accounting for one-time costs like 澳洲幸运5官方开奖结果体彩网:asset amortization and 澳洲幸运5官方开奖结果体彩网:acquisition-related costs, Johnson & Johnson's 澳洲幸运5官方开奖结果体彩网:adjusted net income came ﷺin at $4.94 billion, just above the $4.88 billion🌠 analyst consensus.

The company also outlined its 澳洲幸运5官方开奖结果体彩网:projections for fiscal 2025, as it expects revenue between $89.2 billion to $90 billion, along with an adjusted 澳洲幸运5官方开奖结果体彩网:earnings per share range of $10.50 to $10.70. Analysts currently project a la🅷rger revenue figure at $91.18 billion, and adjusted EPS of $10.54, per Visible Alpha estimates.

Sales in the company's two divisions of pharmaceuticals and medical technology each rose from the same time last year by 4.4% and 6.7%, respectively.

Shares of Johnson & Johnson were down more than 1% Wednesday morning.